196 related articles for article (PubMed ID: 25875742)
1. Osteopontin: a potential biomarker of Gaucher disease.
Vairo F; Sperb-Ludwig F; Wilke M; Michellin-Tirelli K; Netto C; Neto EC; Schwartz I
Ann Hematol; 2015 Jul; 94(7):1119-25. PubMed ID: 25875742
[TBL] [Abstract][Full Text] [Related]
2. Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.
Stirnemann J; Boutten A; Vincent C; Mekinian A; Heraoui D; Fantin B; Fain O; Mentré F; Belmatoug N
Blood Cells Mol Dis; 2011 Jan; 46(1):34-8. PubMed ID: 21084203
[TBL] [Abstract][Full Text] [Related]
3. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
4. Brain-derived neurotrophic factor expression increases after enzyme replacement therapy in Gaucher disease.
Vairo F; Sperb-Ludwig F; Wilke M; Michellin-Tirelli K; Netto C; Neto EC; Doederlein Schwartz IV
J Neuroimmunol; 2015 Jan; 278():190-3. PubMed ID: 25468270
[TBL] [Abstract][Full Text] [Related]
5. [Comparison and clinical application of two methods for determination of plasma chitotriosidase activity].
Wang Y; Zhang HW; Ye J; Qiu WJ; Han LS; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):834-8. PubMed ID: 23302614
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
Boomsma JM; van Dussen L; Wiersma MG; Groener JE; Aerts JM; Maas M; Hollak CE
Blood Cells Mol Dis; 2010 Mar; 44(3):181-7. PubMed ID: 20074983
[TBL] [Abstract][Full Text] [Related]
7. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
8. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
9. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring.
Irún P; Alfonso P; Aznarez S; Giraldo P; Pocovi M
Clin Biochem; 2013 Dec; 46(18):1804-7. PubMed ID: 24060732
[TBL] [Abstract][Full Text] [Related]
10. Management of women with Gaucher disease in the reproductive age.
Rosenbaum H
Thromb Res; 2015 Feb; 135 Suppl 1():S49-51. PubMed ID: 25903536
[TBL] [Abstract][Full Text] [Related]
11. Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
[TBL] [Abstract][Full Text] [Related]
12. Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease.
Reed MC; Bauernfreund Y; Cunningham N; Beaton B; Mehta AB; Hughes DA
Gene; 2018 Dec; 678():196-206. PubMed ID: 30099023
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard.
Mirzaian M; Wisse P; Ferraz MJ; Gold H; Donker-Koopman WE; Verhoek M; Overkleeft HS; Boot RG; Kramer G; Dekker N; Aerts JM
Blood Cells Mol Dis; 2015 Apr; 54(4):307-14. PubMed ID: 25842368
[TBL] [Abstract][Full Text] [Related]
14. Blood oxidative stress markers in Gaucher disease patients.
Roversi FM; Galdieri LC; Grego BH; Souza FG; Micheletti C; Martins AM; D'Almeida V
Clin Chim Acta; 2006 Feb; 364(1-2):316-20. PubMed ID: 16125160
[TBL] [Abstract][Full Text] [Related]
15. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
16. [Plasma chitotriosidase activity in Argentinian patients with Gaucher disease, various lysosomal diseases and other inherited metabolic disorders].
Dodelson de Kremer R; Paschini de Capra A; Angaroni CJ; Giner de Ayala A
Medicina (B Aires); 1997; 57(6):677-84. PubMed ID: 9674188
[TBL] [Abstract][Full Text] [Related]
17. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
18. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
19. Endocrinological and metabolic profile of Gaucher disease patients treated with enzyme replacement therapy.
Kilic A; Emecen Sanli M; Ozsaydı Aktasoglu E; Gokalp S; Biberoğlu G; Inci A; Okur I; Suheyl Ezgu F; Tumer L
J Pediatr Endocrinol Metab; 2024 May; 37(5):413-418. PubMed ID: 38624096
[TBL] [Abstract][Full Text] [Related]
20. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients.
Rolfs A; Giese AK; Grittner U; Mascher D; Elstein D; Zimran A; Böttcher T; Lukas J; Hübner R; Gölnitz U; Röhle A; Dudesek A; Meyer W; Wittstock M; Mascher H
PLoS One; 2013; 8(11):e79732. PubMed ID: 24278166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
